Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars

Executive Summary

The company will not commercialize an insulin glargine copy already tentatively approved by FDA as Lusduna, but says it remains committed to biosimilars in oncology and immunology.

Advertisement

Related Content

Biocon Staying Firm On Insulins Path, Including Glargine
Biocon Staying Firm On Insulins Path, Including Glargine
FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market
Exclusive Remicade Contracts Are Slowing Biosimilar Uptake
FDA Makes It Official With Basaglar Approval For Diabetes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123986

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel